106 related articles for article (PubMed ID: 11414524)
41. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.
Rex JH; Nelson PW; Paetznick VL; Lozano-Chiu M; Espinel-Ingroff A; Anaissie EJ
Antimicrob Agents Chemother; 1998 Jan; 42(1):129-34. PubMed ID: 9449272
[TBL] [Abstract][Full Text] [Related]
42. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints.
Pittrow L; Penk A
Mycoses; 1997; 40(1-2):25-32. PubMed ID: 9260478
[TBL] [Abstract][Full Text] [Related]
43. Management of neonatal candidiasis. Neonatal Candidiasis Study Group.
Rowen JL; Tate JM
Pediatr Infect Dis J; 1998 Nov; 17(11):1007-11. PubMed ID: 9849983
[TBL] [Abstract][Full Text] [Related]
44. Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia.
Kubiak DW; Farmakiotis D; Arons V; Hollins RM; Rostas SE; Weiser LM; Baden LR; Marty FM; Koo S
Diagn Microbiol Infect Dis; 2016 Mar; 84(3):223-6. PubMed ID: 26763713
[TBL] [Abstract][Full Text] [Related]
45. [Candida hellenica Candidemia Occurred After Esophagus Surgery].
Ateş U; Gurbanova A; Yiğitoğlu FN; Kalkancı A
Mikrobiyol Bul; 2020 Apr; 54(2):334-338. PubMed ID: 32723288
[TBL] [Abstract][Full Text] [Related]
46. [Antifungal drugs in the treatment of systemic candidiasis: susceptibility to antifungal drugs, drug resistance, pharmacological data].
Datry A; Thellier M; Traoré B; Alfa Cissé O; Danis M
Ann Fr Anesth Reanim; 2001 Apr; 20(4):389-93. PubMed ID: 11392251
[TBL] [Abstract][Full Text] [Related]
47. Etest for antifungal susceptibility testing of yeasts.
Espinel-Ingroff A
Diagn Microbiol Infect Dis; 1994 Aug; 19(4):217-20. PubMed ID: 7851084
[TBL] [Abstract][Full Text] [Related]
48. Fluconazole: optimized antifungal therapy based on pharmacokinetics.
Silling G
Mycoses; 2002; 45 Suppl 3():39-41. PubMed ID: 12690970
[TBL] [Abstract][Full Text] [Related]
49. Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing.
Cuesta I; Bielza C; Larrañaga P; Cuenca-Estrella M; Laguna F; Rodriguez-Pardo D; Almirante B; Pahissa A; Rodríguez-Tudela JL
Antimicrob Agents Chemother; 2009 Jul; 53(7):2949-54. PubMed ID: 19433568
[TBL] [Abstract][Full Text] [Related]
50. [Invasive candidiasis in selected heamatology departments in the Czech Republic and Slovakia - microbiological results of the CAN CELL project].
Kocmanová I; Drgoňa L; Ráčil Z; Chrenková V; Olišarová P; Mallátová N; Haber J; Lisolová M; Bendová E; Dobiáš R; Dobiášová S
Klin Mikrobiol Infekc Lek; 2011 Feb; 17(1):5-10. PubMed ID: 21452117
[TBL] [Abstract][Full Text] [Related]
51. [Clinical analysis of 8 cases of neonatal septicemia caused by Candida haemulonii in neonatal intensive care unit].
Jie Q; Lin S; Zhang H; Hu Y; Huang X; Chen S; Chen S; Lin Z
Zhonghua Er Ke Za Zhi; 2016 Mar; 54(3):197-200. PubMed ID: 26957065
[TBL] [Abstract][Full Text] [Related]
52. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.
Ghannoum MA; Rex JH; Galgiani JN
J Clin Microbiol; 1996 Mar; 34(3):489-95. PubMed ID: 8904400
[TBL] [Abstract][Full Text] [Related]
53. Cryptococcus liquefaciens isolated from the hand of a healthcare professional in a neonatal intensive care unit.
Alves PGV; de Paula Menezes R; de Oliveira Brito M; de Oliveira Faria G; Silva NBS; Cruvinel RS; Penatti MPA; Dos Santos Pedroso R; de Brito Röder DVD
Braz J Microbiol; 2021 Dec; 52(4):2085-2089. PubMed ID: 34545554
[TBL] [Abstract][Full Text] [Related]
54. Antifungal Susceptibility Testing Practices at Acute Care Hospitals Enrolled in the National Healthcare Safety Network, United States, 2011-2015.
Vallabhaneni S; Sapiano M; Weiner LM; Lockhart SR; Magill S
Open Forum Infect Dis; 2017; 4(4):ofx175. PubMed ID: 29026868
[TBL] [Abstract][Full Text] [Related]
55. Personal opinion: Can antifungal sensitivity tests predict clinical treatment outcomes?
Odds FC
Rev Iberoam Micol; 1997 Sep; 14(3):83-4. PubMed ID: 17655379
[No Abstract] [Full Text] [Related]
56. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
57. Changing epidemiology of candidemia in a medical center in middle Taiwan.
Hii IM; Chang HL; Lin LC; Lee YL; Liu YM; Liu CE; Chen CH; Cheng YR; Chang CY
J Microbiol Immunol Infect; 2015 Jun; 48(3):306-15. PubMed ID: 24113067
[TBL] [Abstract][Full Text] [Related]
58. Clinical features of patients with infections caused by Candida guilliermondii and Candida fermentati and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10.
Chen CY; Huang SY; Tang JL; Tsay W; Yao M; Ko BS; Chou WC; Tien HF; Hsueh PR
J Antimicrob Chemother; 2013 Nov; 68(11):2632-5. PubMed ID: 23766486
[TBL] [Abstract][Full Text] [Related]
59. Distribution and drug susceptibilities of Candida species causing candidemia from a medical center in central Taiwan.
Chang TP; Ho MW; Yang YL; Lo PC; Lin PS; Wang AH; Lo HJ
J Infect Chemother; 2013 Dec; 19(6):1065-71. PubMed ID: 23732308
[TBL] [Abstract][Full Text] [Related]
60. Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial.
Mootsikapun P; Hsueh PR; Talwar D; Co VM; Rajadhyaksha V; Ong ML
BMC Infect Dis; 2013 May; 13():219. PubMed ID: 23676114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
